Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06423430 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

Study acronym: TRANSCEND
StatusRecruiting
PhaseNot applicable
Started2024-09-11
View on ClinicalTrials.gov ↗

Amendment history

2026-08-26
Study Status, Contacts/Locations v28
Study sites24→25
2026-06-25
Study Status, Contacts/Locations, References v27
Study sitescontacts updated at 13 of 24 sites
2026-06-03
Study Status, Contacts/Locations v26
Re-verified, no change to tracked fields
2026-05-20
Study Status, Contacts/Locations v25
Trial sites reduced: 28 → 24 locations
2026-04-14
Study Status, Contacts/Locations v24
Trial sites expanded: 25 → 28 locations
Show 23 earlier versions
2026-03-13
Study Status, Contacts/Locations v23
Study sites24→25
2026-03-11
Study Status, Contacts/Locations v22
Study sitescontacts updated at 1 of 24 sites
2026-02-11
Study Status, Contacts/Locations v21
Study sitescontacts updated at 1 of 24 sites
2026-02-10
Study Status, Contacts/Locations v20
Study sites23→24
2026-01-07
Study Status, Contacts/Locations v19
Study sitescontacts updated at 3 of 23 sites
2025-12-11
Study Status, Contacts/Locations v18
Study sites22→23
2025-10-02
Study Status, Contacts/Locations v17
Study sitescontacts updated at 14 of 22 sites
2025-09-16
Study Status, Outcome Measures, Eligibility, Contacts/Locations v16
Secondary endpoints3 to 5 entries
MADRSPercent Response Rates Changetime in MADRS Scoreresponse Percent time in MADRS partial response Percent time in CGI-I partial response MADRS RemissionResponse RatesRate Q-LES-Q score change
Primary endpoints1 to 2 entries
TheCGI-I primaryresponse effectivenessrate Change endpoint:in MontgomeryMADRS Asbergtotal Depression Rating Scale (MADRS) Rate of Responsescore
Study sitesdetails revised at 3 of 22 sites
2025-07-07
Study Status, Contacts/Locations v15
Study sitesdetails revised at 3 of 22 sites
2025-06-03
Study Status, Contacts/Locations v14
Study sitesdetails revised at 1 of 22 sites
2025-05-01
Study Status, Contacts/Locations v13
Study sitescontacts updated at 1 of 22 sites
2025-04-29
Study Status, Contacts/Locations v12
Study sitesdetails revised at 1 of 22 sites
2025-04-21
Study Status, Contacts/Locations v11
Study sitesdetails revised at 3 of 22 sites
2025-03-31
Study Status, Contacts/Locations v10
Study sitesdetails revised at 1 of 22 sites
2025-03-26
Study Status, Contacts/Locations v9
Study sites20→22
2025-03-03
Study Status, Contacts/Locations v8
Study sitesdetails revised at 1 of 20 sites
2025-02-17
Study Status, Contacts/Locations v7
Study sitesdetails revised at 3 of 20 sites
2025-01-31
Study Status, Contacts/Locations v6
Study sitesdetails revised at 20 of 20 sites
2024-12-04
Study Status, Conditions, Outcome Measures, Eligibility, Contacts/Locations v5
Primary endpoints1 entry, revised
The primary effectiveness endpoint: Montgomery Asberg Depression Rating Scale (MADRS) Rate of Response
Study sitescontacts updated at 20 of 20 sites
2024-09-27
Study Status, Contacts/Locations v4
Study sites20 entries, revised
Pennsylvania Hospital of the University of Pennsylvania
2024-09-13
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v3
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2024-08→confirmed 2024-09-11
Study sitesdetails revised at 20 of 20 sites
2024-08-05
Study Status, Outcome Measures v2
Secondary endpointsdetails revised at 2 of 3 entries
2024-06-02
Withheld→Not Yet Recruiting Study Identification, Study Status, Sponsor/Collaborators, Oversight, Study Description, Conditions, Study Design, Arms and Interventions, Outcome Measures, Eligibility, Contacts/Locations, IPDSharing v1
Trial statusWithheld→Not Yet Recruiting
Primary completion datenot stated→2027-04
Completion datenot stated→2029-04
Start datenot stated→2024-08
Lead sponsor[Redacted]→Abbott Medical Devices
Study title+11 characters
[TrialTreatment ofResistAnt deviceDepression thatSubcallosal isCingulatE notNetwork approvedDBS or cleared by the U.S. FDA](TRANSCEND)
2024-05-16
Original filing
The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.
Trial Details
NCT Number NCT06423430
Lead Sponsor Abbott Medical Devices
Conditions Treatment Resistant Depression
Enrollment 100 participants
Start Date 2024-09-11
Primary Completion 2027-04 (estimated)
Study Completion 2029-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-28